Close this search box.

Supporting the Entire Life Cycle: Biotech Company

RNA Advisors Supported a Biotech Company from Inception through IPO through M&A


RNA began working with a newly formed private biotechnology company with a technology platform applicable to drug development in various disease areas.

RNA team members worked with several of the company’s management team when they were at a prior biotechnology company that was ultimately acquired by a large pharmaceutical company.


Performed secondary market research to assess the attractiveness of various disease areas to explore for initial drug development efforts.

Provided independent valuations for 409A and other tax and financial reporting purposes up through the company’s initial public offering.

Developed financial models, forecasts, and sensitivity analyses to support the company’s collaboration and partnering discussions with multiple large pharmaceutical companies, as well as its eventual acquisition.


RNA’s research, financial modeling, valuation and transaction support services assisted the company through key inflection points and provided company management and its board greater confidence in their decision-making process.

RNA continues to work with former company executives at new biotechnology startups that they joined.

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.